Tango Therapeutics, Inc.
TNGX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.25 | 0.75 | -0.19 | 0.28 |
| FCF Yield | -39.19% | -12.76% | -18.34% | -9.03% |
| EV / EBITDA | -2.13 | -8.13 | -5.64 | -9.39 |
| Quality | ||||
| ROIC | -51.94% | -31.87% | -28.90% | -12.65% |
| Gross Margin | 100.00% | -215.38% | 83.80% | 94.69% |
| Cash Conversion Ratio | 1.01 | 1.16 | 1.01 | 1.02 |
| Growth | ||||
| Revenue 3-Year CAGR | 19.17% | -0.47% | 48.08% | 14.54% |
| Free Cash Flow Growth | -10.67% | -2.34% | -90.29% | -188.97% |
| Safety | ||||
| Net Debt / EBITDA | 0.23 | 0.25 | 0.17 | 2.47 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 7.10 | 3.47 |
| Cash Conversion Cycle | 0.00 | -8.82 | -322.77 | -473.95 |